Get the Stockscreener App
12.30
1.23%
0.15
After Hours:
12.30
Corbus Pharmaceuticals Holdings Inc stock is traded at $12.30, with a volume of 784.01K.
It is up +1.23% in the last 24 hours and down -17.06% over the past month.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
See More
Previous Close:
$12.15
Open:
$12.16
24h Volume:
784.01K
Relative Volume:
3.01
Market Cap:
$150.74M
Revenue:
$1.54M
Net Income/Loss:
$-38.70M
P/E Ratio:
-2.6338
EPS:
-4.67
Net Cash Flow:
$-36.86M
1W Performance:
-27.69%
1M Performance:
-17.06%
6M Performance:
+57.89%
1Y Performance:
-27.30%
1-Day Range:
$11.64
$12.51
1-Week Range:
$11.59
$18.11
52-Week Range:
$4.64
$20.77
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Company Profile
Name
Corbus Pharmaceuticals Holdings Inc
Sector
Industry
Phone
617-963-0103
Address
500 RIVER RIDGE DRIVE, NORWOOD, MA
Compare CRBP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRBP
Corbus Pharmaceuticals Holdings Inc
|
12.30 | 148.90M | 1.54M | -38.70M | -36.86M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | B. Riley Securities | Buy |
| Feb-28-25 | Initiated | William Blair | Outperform |
| Dec-02-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Initiated | Wedbush | Outperform |
| Jul-22-24 | Resumed | H.C. Wainwright | Buy |
| Jun-26-24 | Initiated | B. Riley Securities | Buy |
| Jun-03-24 | Reiterated | Oppenheimer | Outperform |
| May-13-24 | Initiated | RBC Capital Mkts | Outperform |
| Mar-06-24 | Upgrade | Jefferies | Hold → Buy |
| Sep-08-20 | Downgrade | BTIG Research | Buy → Neutral |
| Sep-08-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-08-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-08-20 | Downgrade | ROTH Capital | Buy → Neutral |
| Jul-07-20 | Initiated | ROTH Capital | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| Mar-26-20 | Initiated | Nomura | Buy |
| Apr-05-19 | Initiated | Jefferies | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jan-11-19 | Reiterated | Cantor Fitzgerald | Overweight |
| Dec-26-18 | Initiated | H.C. Wainwright | Buy |
| Dec-07-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-18 | Initiated | B. Riley FBR | Buy |
| Jan-19-18 | Initiated | Raymond James | Outperform |
| Dec-14-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-08-17 | Reiterated | Noble Financial | Buy |
| Sep-29-17 | Resumed | Noble Financial | Buy |
| Mar-30-17 | Reiterated | Cantor Fitzgerald | Overweight |
| Nov-15-16 | Reiterated | JMP Securities | Mkt Outperform |
| Nov-11-16 | Reiterated | Noble Financial | Buy |
View All
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Latest News
Corbus Pharmaceuticals Holdings Inc expected to post a loss of $1.71 a shareEarnings Preview - TradingView
Is Corbus Pharmaceuticals Holdings Inc. (3371) stock a top dividend aristocrat candidateMarket Volume Report & Expert Curated Trade Setup Alerts - newser.com
Corbus Pharmaceuticals Announces $70.5M Public Offering - TipRanks
Is it time to cut losses on Corbus Pharmaceuticals Holdings Inc.Weekly Volume Report & Step-by-Step Swing Trade Plans - newser.com
Form 424B5 Corbus Pharmaceuticals - StreetInsider
Is Corbus Pharmaceuticals Holdings Inc. stock a contrarian buyPortfolio Performance Report & AI Forecasted Entry/Exit Points - newser.com
Published on: 2025-11-03 05:13:38 - newser.com
Published on: 2025-11-03 05:07:17 - newser.com
Quantitative breakdown of Corbus Pharmaceuticals Holdings Inc. recent move2025 Top Gainers & High Yield Stock Recommendations - newser.com
Understanding Corbus Pharmaceuticals Holdings Inc.’s price movement2025 Trade Ideas & Fast Exit and Entry Trade Guides - newser.com
Will breakout in Corbus Pharmaceuticals Holdings Inc. lead to full recoveryJuly 2025 Final Week & Pattern Based Trade Signal System - newser.com
AlphaQuest LLC Has $218,000 Holdings in Corbus Pharmaceuticals Holdings, Inc. $CRBP - MarketBeat
How institutional buying supports Corbus Pharmaceuticals Holdings Inc. stockEarnings Growth Summary & Free Expert Approved Momentum Trade Ideas - newser.com
Will Corbus Pharmaceuticals Holdings Inc. (3371) stock remain on Wall Street radarMarket Sentiment Review & Free Technical Pattern Based Buy Signals - newser.com
Short interest data insights for Corbus Pharmaceuticals Holdings Inc.Earnings Overview Summary & Low Drawdown Momentum Trade Ideas - newser.com
Can Corbus Pharmaceuticals Holdings Inc. stock reach $100 price targetIPO Watch & Low Drawdown Investment Strategies - newser.com
Why Corbus Pharmaceuticals Holdings Inc. stock is favored by pension fundsTrade Ideas & Stepwise Trade Signal Implementation - newser.com
Can swing trading help recover from Corbus Pharmaceuticals Holdings Inc. losses2025 Support & Resistance & Stock Market Timing Techniques - newser.com
How to build a dashboard for Corbus Pharmaceuticals Holdings Inc. stockOil Prices & Growth Focused Stock Reports - newser.com
Corbus Pharmaceuticals slumps 17%, prices $75M at $13 per share - MSN
Published on: 2025-11-02 11:47:57 - newser.com
Published on: 2025-11-02 07:07:31 - newser.com
Comparing Corbus Pharmaceuticals Holdings Inc. in custom built stock radarsMarket Growth Report & Reliable Entry Point Trade Alerts - newser.com
Published on: 2025-11-01 11:30:29 - newser.com
Published on: 2025-11-01 08:40:29 - newser.com
Corbus Pharmaceuticals provides preliminary Q3 cash estimate in SEC filing By Investing.com - Investing.com Australia
Published on: 2025-11-01 04:04:11 - newser.com
Corbus prices $75 million public offering of common stock By Investing.com - Investing.com Philippines
Corbus Pharmaceuticals: Downgrade To Hold Due To Narrow Focus Window (NASDAQ:CRBP) - Seeking Alpha
Corbus Pharmaceuticals stock plunges after $75 million public offering By Investing.com - Investing.com UK
Corbus Pharmaceuticals stock plunges after $75 million public offering - Investing.com
Corbus Pharmaceuticals announces common stock offering By Investing.com - Investing.com Australia
Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Passes Above 50-Day Moving AverageShould You Sell? - MarketBeat
Roku, SPS Commerce, Newell Brands And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga
Corbus Pharmaceuticals (CRBP) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Published on: 2025-10-31 05:15:03 - newser.com
Published on: 2025-10-31 05:14:27 - newser.com
Corbus Pharmaceuticals Prices $75 Million Offering; Shares Down Pre-Bell - MarketScreener
Corbus prices $75 million public offering of common stock - Investing.com
How Corbus Pharmaceuticals Holdings Inc. (3371) stock compares with market leaders2025 Risk Factors & Free Safe Entry Trade Signal Reports - newser.com
Corbus Pharmaceuticals Announces Pricing of Public Offering - The Manila Times
Corbus Pharmaceuticals announces pricing of public offering at $13.00 per share - MarketScreener
Corbus Pharmaceuticals Holdings Inc Stock (CRBP) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):